IMRX - Immuneering Corp - Ordinary Shares Class A
IEX Last Trade
1.11
-0.050 -4.505%
Share volume: 264,507
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.16
-0.05
-4.31%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-10 | 2022-08-10 | 2022-11-10 | 2023-03-06 | 2023-05-04 | 2023-08-03 | 2023-11-09 | |
| Assets | ||||||||
| Total Assets | 152.447 M | 142.050 M | 133.692 M | 122.367 M | 107.696 M | 124.895 M | 113.881 M | |
| Current Assets | 139.530 M | 129.170 M | 120.025 M | 108.747 M | 94.234 M | 111.507 M | 100.583 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.480 M | 890.409 K | 2.757 M | 3.210 M | 2.697 M | 2.522 M | 3.340 M | |
| Short Term Investments | 1.480 M | 890.409 K | 2.757 M | 3.210 M | 2.697 M | 2.522 M | 3.340 M | |
| Total Receivables | 279.614 K | 178.425 K | 70.180 K | 12.417 K | 1.046 K | 0.000 | 0.000 | |
| Current Cash | 137.771 M | 128.101 M | 117.197 M | 105.525 M | 91.536 M | 108.985 M | 97.243 M | |
| Total Non-current Assets | 12.917 M | 12.880 M | 13.667 M | 13.620 M | 13.463 M | 13.388 M | 13.298 M | |
| Property Plant Equipment | 874.569 K | 985.007 K | 1.310 M | 1.370 M | 1.325 M | 1.366 M | 1.393 M | |
| Other Assets | 4.921 M | 4.781 M | 5.250 M | 5.151 M | 5.046 M | 4.938 M | 4.828 M | |
| Intangible Assets | 430.897 K | 423.580 K | 416.263 K | 408.947 K | 401.630 K | 394.313 K | 386.997 K | |
| Goodwill | 6.690 M | 6.690 M | 6.690 M | 6.690 M | 6.690 M | 6.690 M | 6.690 M | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 152.447 M | 142.050 M | 133.692 M | 122.367 M | 107.696 M | 124.895 M | 113.881 M | |
| Total liabilities | 8.391 M | 8.455 M | 11.798 M | 12.517 M | 9.907 M | 9.791 M | 9.863 M | |
| Total current liabilities | 3.674 M | 3.801 M | 7.256 M | 8.054 M | 5.526 M | 5.479 M | 5.622 M | |
| Accounts Payable | 1.642 M | 1.240 M | 2.338 M | 3.155 M | 2.724 M | 2.693 M | 1.941 M | |
| Other liabilities | 9.898 K | 9.898 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 265.419 K | 286.374 K | 308.694 K | 378.723 K | 363.238 K | 332.675 K | 301.633 K | |
| Long term debt | 4.708 M | 4.645 M | 4.543 M | 4.463 M | 4.381 M | 4.312 M | 4.241 M | |
| Other liabilities | 9.898 K | 9.898 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 144.056 M | 133.595 M | 121.893 M | 109.850 M | 97.790 M | 115.104 M | 104.018 M | |
| Common stock | 26.359 M | 26.386 M | 26.394 M | 26.408 M | 26.442 M | 28.647 M | 29.266 M | |
| Retained earnings | -72.170 M | -83.697 M | -96.541 M | -109.787 M | -123.391 M | -135.580 M | -148.175 M |